Furthermore, a proportion of patients on prolonged TKI therapy will become persistently BCR-ABL negative, providing the tantalizing hope that TKIs may be curing some CML patients. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.